Free Trial

STERIS (STE) Competitors

STERIS logo
$221.16 -2.85 (-1.27%)
Closing price 03:59 PM Eastern
Extended Trading
$221.16 0.00 (0.00%)
As of 04:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

STE vs. BDX, EW, RMD, IDXX, DXCM, PODD, BAX, HOLX, GMED, and MASI

Should you be buying STERIS stock or one of its competitors? The main competitors of STERIS include Becton, Dickinson and Company (BDX), Edwards Lifesciences (EW), ResMed (RMD), IDEXX Laboratories (IDXX), DexCom (DXCM), Insulet (PODD), Baxter International (BAX), Hologic (HOLX), Globus Medical (GMED), and Masimo (MASI). These companies are all part of the "health care equipment" industry.

STERIS vs.

STERIS (NYSE:STE) and Becton, Dickinson and Company (NYSE:BDX) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, media sentiment, community ranking, dividends, valuation and earnings.

STERIS pays an annual dividend of $2.28 per share and has a dividend yield of 1.0%. Becton, Dickinson and Company pays an annual dividend of $4.16 per share and has a dividend yield of 2.1%. STERIS pays out 48.4% of its earnings in the form of a dividend. Becton, Dickinson and Company pays out 69.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. STERIS has increased its dividend for 20 consecutive years and Becton, Dickinson and Company has increased its dividend for 53 consecutive years. Becton, Dickinson and Company is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

STERIS has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500. Comparatively, Becton, Dickinson and Company has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500.

STERIS has a net margin of 8.66% compared to Becton, Dickinson and Company's net margin of 8.47%. Becton, Dickinson and Company's return on equity of 15.74% beat STERIS's return on equity.

Company Net Margins Return on Equity Return on Assets
STERIS8.66% 13.91% 8.64%
Becton, Dickinson and Company 8.47%15.74%7.29%

Becton, Dickinson and Company has higher revenue and earnings than STERIS. Becton, Dickinson and Company is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
STERIS$5.40B4.03$378.24M$4.7146.96
Becton, Dickinson and Company$20.64B2.81$1.71B$6.0233.56

In the previous week, Becton, Dickinson and Company had 18 more articles in the media than STERIS. MarketBeat recorded 39 mentions for Becton, Dickinson and Company and 21 mentions for STERIS. STERIS's average media sentiment score of 1.42 beat Becton, Dickinson and Company's score of 1.01 indicating that STERIS is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
STERIS
16 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Becton, Dickinson and Company
26 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Positive

Becton, Dickinson and Company received 264 more outperform votes than STERIS when rated by MarketBeat users. Likewise, 62.42% of users gave Becton, Dickinson and Company an outperform vote while only 59.16% of users gave STERIS an outperform vote.

CompanyUnderperformOutperform
STERISOutperform Votes
339
59.16%
Underperform Votes
234
40.84%
Becton, Dickinson and CompanyOutperform Votes
603
62.42%
Underperform Votes
363
37.58%

STERIS presently has a consensus target price of $258.75, suggesting a potential upside of 16.99%. Becton, Dickinson and Company has a consensus target price of $275.71, suggesting a potential upside of 36.48%. Given Becton, Dickinson and Company's stronger consensus rating and higher probable upside, analysts plainly believe Becton, Dickinson and Company is more favorable than STERIS.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
STERIS
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80
Becton, Dickinson and Company
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
3.00

94.7% of STERIS shares are held by institutional investors. Comparatively, 87.0% of Becton, Dickinson and Company shares are held by institutional investors. 1.1% of STERIS shares are held by company insiders. Comparatively, 0.4% of Becton, Dickinson and Company shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Becton, Dickinson and Company beats STERIS on 12 of the 21 factors compared between the two stocks.

Remove Ads
Get STERIS News Delivered to You Automatically

Sign up to receive the latest news and ratings for STE and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

STE vs. The Competition

MetricSTERISSurgical appliances & supplies IndustryMedical SectorNYSE Exchange
Market Cap$21.73B$8.62B$5.33B$18.52B
Dividend Yield1.05%1.71%5.11%4.24%
P/E Ratio46.9618.5321.8131.16
Price / Sales4.0372.21379.3725.68
Price / Cash15.7319.6738.1517.53
Price / Book3.384.866.464.29
Net Income$378.24M$284.66M$3.20B$1.02B
7 Day Performance6.20%5.71%6.63%6.58%
1 Month Performance-2.59%-1.66%-8.50%-6.89%
1 Year Performance9.89%-21.45%10.47%1.21%

STERIS Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
STE
STERIS
4.5996 of 5 stars
$221.17
-1.3%
$258.75
+17.0%
+9.9%$21.73B$5.40B46.9616,000Positive News
BDX
Becton, Dickinson and Company
4.833 of 5 stars
$204.88
-1.2%
$275.71
+34.6%
-12.6%$58.83B$20.64B34.0377,000Short Interest ↑
Analyst Revision
Positive News
High Trading Volume
EW
Edwards Lifesciences
4.5147 of 5 stars
$69.00
-0.5%
$79.95
+15.9%
-22.6%$40.56B$5.44B9.9017,300Insider Trade
News Coverage
Positive News
RMD
ResMed
4.4085 of 5 stars
$213.06
+3.8%
$249.73
+17.2%
+15.4%$31.29B$4.93B25.158,160Analyst Revision
Positive News
High Trading Volume
IDXX
IDEXX Laboratories
4.8013 of 5 stars
$378.99
-3.7%
$533.75
+40.8%
-18.7%$30.71B$3.90B35.5210,800Analyst Downgrade
Positive News
High Trading Volume
DXCM
DexCom
4.907 of 5 stars
$61.63
+3.0%
$99.82
+62.0%
-50.5%$24.17B$4.03B43.107,600Positive News
Gap Down
High Trading Volume
PODD
Insulet
4.5741 of 5 stars
$256.23
+4.5%
$292.06
+14.0%
+45.8%$17.99B$2.07B44.252,600Short Interest ↓
Positive News
BAX
Baxter International
4.556 of 5 stars
$28.61
-0.6%
$38.56
+34.8%
-29.8%$14.67B$10.64B-22.3560,000
HOLX
Hologic
4.8247 of 5 stars
$61.27
+0.7%
$84.62
+38.1%
-23.9%$13.75B$4.04B19.336,940Positive News
High Trading Volume
GMED
Globus Medical
4.7611 of 5 stars
$70.74
+2.8%
$97.09
+37.2%
+41.3%$9.73B$2.52B94.322,600Short Interest ↑
News Coverage
Positive News
Gap Down
MASI
Masimo
4.3886 of 5 stars
$150.36
+4.1%
$194.80
+29.6%
+11.4%$8.12B$2.09B103.706,200Positive News
Gap Down
Remove Ads

Related Companies and Tools


This page (NYSE:STE) was last updated on 4/15/2025 by MarketBeat.com Staff
From Our Partners